Mesoblast Limited
NASDAQ: MESO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Silviu Itescu
- Employees
- 73
- Headquarters
- Melbourne, Australia
- IPO year
- 2010
- Market cap
- $2.0B
- Website
- https://www.mesoblast.com
Loading MESO…
Loading profile data…Frequently asked questions about MESO
What does Mesoblast Limited (MESO) do?
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthop...
Where does MESO trade?
Mesoblast Limited (MESO) trades on the NASDAQ Global Select.
What sector is MESO in?
Mesoblast Limited (MESO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mesoblast Limited?
Silviu Itescu is the chief executive officer of Mesoblast Limited (MESO).
Where is Mesoblast Limited headquartered?
Mesoblast Limited is headquartered in Australia.
Does MESO pay a dividend?
Mesoblast Limited (MESO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MESO go public?
Mesoblast Limited (MESO) completed its initial public offering in 2010.
Is MESO an ADR?
Yes — MESO is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Mesoblast Limited reporting and dividends follow the underlying issuer.